PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced preclinical & clinical data from three studies supporting of the potential of belinostat in multiple orphan oncology indications, including results from its Phase I/II trial of belinostat in combination with standard chemotherapy in patients with soft tissue sarcomas (STS).
Help employers find you! Check out all the jobs and post your resume.
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced preclinical & clinical data from three studies supporting of the potential of belinostat in multiple orphan oncology indications, including results from its Phase I/II trial of belinostat in combination with standard chemotherapy in patients with soft tissue sarcomas (STS).
Help employers find you! Check out all the jobs and post your resume.
